Diagnostics Channel NavClinical Channel NavInformatics Channel NavCancer Channel NavRegister Nav
MMTC15_Header  
MMTC M Header 

Early Stage Molecular Diagnostics Partnering Forum 

Speaking proposals are still being accepted!  Click here to submit a proposal for review. 

Early Stage Molecular Diagnostics - Overview | Day 1Joint Sessions | Emerging Targeted Oncology 

Downloads
Early Stage Molecular Diagnostics PDF | Emerging Targeting Oncology PDF

Particularly efficient for promoting discussion of partnerships, the Early Stage Molecular Diagnostics Partnering Forum is designed for both the emerging companies with promising technology and applications, and more established companies looking to collaborate with these companies.

Reasons to Attend

  • Opportunities for scheduled one-on-one meetings and unscheduled networking with company presenters
  • 20 Companies focused on Cancer-related diagnostics 
  • 40 Emerging Company Presentations including point-of-care, rapid diagnostic platforms, novel amplification and automated sample processing approaches, diagnostics for infectious disease, cardiovascular, CNS, pregnancy and other disorders
  • Panel Discussions with Program Advisors
  • Diagnostics based on DNA sequencing, genotyping and mutation analysis, gene expression signatures, protein biomarkers and protein signatures, protein post-translational modification and autoantibodies, microbiome analysis

Program Advisory Board Includes:

  • Abbott Molecular
  • BD Diagnostics
  • BioMerieux
  • Bristol Myers Squibb
  • DAKO
  • Diaceutics
  • Genomic Health
  • Gen-Probe
  • Illumina
  • LabCorp
 
  • Leomics Consulting
  • MDX Consulting
  • Medco Health Solutions
  • QIAGEN
  • Roche Diagnostics
  • Scientia Advisors
  • SONY DADC
  • Versant Ventures
 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 



2014 Premier Sponsors:

 Elsevier   

 

NanoString 

 

Quanterix 

 

RemedyMD 

 

Singulex 

 

Thomson Reuters